Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corcept Therapeutics (CORT – Research Report) and Genmab (GMAB – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Corcept Therapeutics (CORT)

Truist Financial analyst Joon Lee reiterated a Buy rating on Corcept Therapeutics today and set a price target of $135.00. The company’s shares closed last Friday at $88.15.

According to TipRanks.com, Lee is a 5-star analyst with an average return of 27.0% and a 55.7% success rate. Lee covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical. ;'>

Currently, the analyst consensus on Corcept Therapeutics is a Strong Buy with an average price target of $135.25, implying a 56.2% upside from current levels. In a report issued on September 25, Canaccord Genuity also maintained a Buy rating on the stock with a $140.00 price target.

See the top stocks recommended by analysts >>

Genmab (GMAB)

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab today and set a price target of $49.00. The company’s shares closed last Friday at $33.56.

According to TipRanks.com, Goonewardene has 0 stars on 0-5 stars ranking scale with an average return of -8.0% and a 38.4% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Allogene Therapeutics, and Autolus Therapeutics. ;'>

Currently, the analyst consensus on Genmab is a Moderate Buy with an average price target of $39.60, a 21.1% upside from current levels. In a report issued on September 23, Guggenheim also upgraded the stock to Buy with a $43.00 price target.

Read More on CORT:

Disclaimer & DisclosureReport an Issue

• Corcept Therapeutics management to meet with Truist
• 3 ‘Outperform’ Healthcare Stocks, According to AI Analyst, 9/10/25
• Corcept Therapeutics price target raised to $140 from $137 at Canaccord
• Corcept Therapeutics’ New Drug Application Accepted by FDA
• Corcept Therapeutics announces FDA acceptance of relacorilant NDA